Ticker: AMH
American Healthcare REIT (AMH)
Real estate
Real Estate
REIT - Residential
Price
31.50
Reco
Hold
Potential
60
Risk
69
Updated
2026-09-10
Forecast impact
Target
+17.9%
target fill 84.8%
Reaction
D5 +0.73% · D10 -2.29%
Impact
Potential 0 · Risk 0
valid until 2026-09-11
Track in portfolio
Price chart
AI recommendation
Analyst forecast
Calendar event
Positive signal
Negative signal
Neutral / update
Hold / informational
B My buy
S My sell
Description
Company and Business Model
American Healthcare REIT (AMH) focuses on acquiring, owning, and managing healthcare-related real estate properties. Its core services include leasing properties to healthcare providers, primarily in the senior housing and medical office sectors. Major business segments encompass skilled nursing facilities, assisted living, and outpatient medical centers. The primary revenue source is rental income from long-term leases with healthcare operators.
Investment Profile
The investment profile of American Healthcare REIT is more aligned with dividend investors due to its consistent dividend yield of 5.1%. The stock exhibits moderate growth potential, making it suitable for those seeking income with some capital appreciation. The overall risk is balanced, appealing to investors looking for stability in the healthcare real estate sector.
Fundamental metrics (experimental) Updated: 2026-09-06
- EPS (TTM) — earnings per share for the last 12 months, $
- 1.26
- Revenue QoQ — quarter-over-quarter revenue growth
- -0.4%
- EPS surprise
- 72.4%
- 20d volatility
- 1.0%
- Dividend yield
- 4.9%
- last ex-date
- 2026-09-15
AI recommendation changes
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-09-04 | Buy | Hold | Weak momentum and high risk; cautious approach advised. |
| 2026-08-27 | Hold | Buy | Stable dividend, but mixed momentum signals present risks. |
| 2026-08-20 | Sell | Hold | Strong EPS surprise and solid dividend yield support growth. |
| 2026-08-12 | Buy | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-27 | Hold | Buy | Strong performance and solid dividend yield support growth. |
| 2026-06-19 | Buy | Hold | Stable dividend, but mixed momentum signals present risks. |
| 2026-06-09 | Hold | Buy | Solid dividend yield, but mixed momentum signals. |
| 2026-06-01 | Buy | Hold | Stable yield; moderate growth; mixed analyst signals. |
| 2026-05-24 | Hold | Buy | Strong EPS surprise and solid dividend yield support growth. |
| 2026-05-16 | Buy | Hold | Stable dividend but negative momentum raises concerns. |
| 2026-05-08 | — | Buy | Stable dividend, but revenue decline raises concerns. |
| 2026-05-03 | Hold | Buy | Компания демонстрирует стабильный дивидендный доход и положительную динамику за последние 20 дней. Несмотря на небольшое снижение выручки, потенциал роста остается высоким благодаря устойчивому спросу в секторе здравоохр |
| 2026-03-30 | Sell | Hold | Компания демонстрирует стабильную дивидендную доходность, но наблюдается снижение выручки и негативная динамика акций за последние месяцы, что вызывает опасения по поводу будущих перспектив. |
| 2026-03-14 | — | Sell | Компания демонстрирует отрицательную динамику цен на акции за последние месяцы, что указывает на высокие риски. Отсутствие данных о прибыли и выручке также делает инвестиции в данный момент менее привлекательными. |
Analyst forecasts
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-08-12 | Morgan Stanley | Target Lowered | 38.5 → 38 | 33.87 |
| 2026-08-03 | RBC Capital | Target Raised | 36 → 37 | 34.35 |
| 2026-07-14 | Barclays | Target Raised | 32 → 36 | 33.8 |
| 2026-07-08 | UBS | Target Raised | 32 → 35 | 33.28 |
| 2026-06-26 | Deutsche Bank | Update | — → 39 | 33.29 |
| 2026-06-17 | Mizuho Securities | Target Raised | 29 → 35 | 32.43 |
| 2026-06-15 | BMO Capital | Target Raised | 36 → 39 | 33.29 |
| 2026-05-27 | Morgan Stanley | Target Lowered | 39 → 38.5 | 32.04 |
| 2026-05-21 | Scotiabank | Target Raised | 31 → 32 | 32.045 |
| 2026-05-19 | UBS | Target Lowered | 33 → 32 | 31.725 |
| 2026-05-18 | Raymond James | Rating Upgraded | — → 35 | 30.61 |
| 2026-04-28 | Compass Point | Update | — → 37.5 | 30.3 |
| 2026-04-27 | Barclays | Target Raised | 31 → 32 | 30.55 |
| 2026-02-23 | RBC Capital | Target Lowered | 38 → 35 | 29.22 |
| 2026-01-13 | Barclays | Target Lowered | 34 → 33 | 30.56 |
| 2026-01-09 | BMO Capital | Rating Downgraded | — → 37 | 31.63 |
| 2026-01-08 | UBS | Target Lowered | 38 → 33 | 31.01 |
| 2026-01-08 | Mizuho Securities | Rating Downgraded | — → 32 | 31.01 |
| 2025-12-19 | Wolfe Research | Target Lowered | 39 → 34.5 | 31.34 |
| 2025-12-15 | Goldman Sachs | Update | — → 37 | 31.115 |
| 2025-11-25 | Wells Fargo | Target Lowered | 38 → 37 | 32.09 |
News Page 1 of 1
Nothing yet